NCT06503614View on ClinicalTrials.gov

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Non-muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
DRUG

Durvalumab

Durvalumab 1500mg IV

DRUG

Monalizumab

Monalizumab 1500mg IV

Trial Locations (2)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Bladder Cancer Advocacy Network

OTHER

lead

John Sfakianos

OTHER